公开(公告)号：WO2011139107A3

公开(公告)日：2012-05-18

申请号：PCT/KR2011003362

申请日：2011-05-04

Applicant: SK CHEMICALS CO LTD ,  RYU JE HO ,  KIM SHIN AE ,  RYU KEUN HO ,  KIM JAE SUN ,  KIM NAM HO ,  HAN HYE YOUNG ,  KIM YONG HYUK ,  YOUN WON-NO ,  LEE YOON-JUNG ,  SON HYUN JOO ,  LEE BONG-YONG ,  PARK SUNG HOON ,  LEE JU YOUNG ,  LEE HYUN JUNG ,  JUNG HOE CHUL ,  SHIN YOUNG AH ,  LEE JUNG A ,  LEE BO RAM ,  SA JOON HO

Inventor： RYU JE HO ,  KIM SHIN AE ,  RYU KEUN HO ,  KIM JAE SUN ,  KIM NAM HO ,  HAN HYE YOUNG ,  KIM YONG HYUK ,  YOUN WON-NO ,  LEE YOON-JUNG ,  SON HYUN JOO ,  LEE BONG-YONG ,  PARK SUNG HOON ,  LEE JU YOUNG ,  LEE HYUN JUNG ,  JUNG HOE CHUL ,  SHIN YOUNG AH ,  LEE JUNG A ,  LEE BO RAM ,  SA JOON HO

IPC: C07D401/04 ,  A61K31/444 ,  A61K31/496 ,  A61P3/06 ,  A61P3/10 ,  C07D401/14 ,  C07D413/14

CPC classification number: C07D401/04 ,  C07D213/81 ,  C07D239/557 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11ß-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11ß-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11ß-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract translation: 提供了吡啶酰胺和嘧啶-4-甲酰胺化合物，其制备方法，含有该组合物的药物组合物，以及使用该化合物作为预防，调节和治疗与糖皮质激素调节有关的疾病的药物的用途 化合物对11β-HSD1酶的选择性抑制活性。 本发明的吡啶酰胺和嘧啶-4-甲酰胺化合物是人源性11β-HSD1酶的选择性抑制剂，可用于预防，调节和治疗与糖皮质激素调节有关的疾病的药剂，其中人源性11β- 涉及HSD1酶，例如代谢综合征，例如1型和2型糖尿病，糖尿病后期并发症，潜伏性自身免疫性糖尿病成人（LAD A），胰岛素耐受综合征，肥胖症，葡萄糖耐量降低（IGT），空腹血糖受损 IFG），葡萄糖耐量受损，血脂异常，动脉粥样硬化，高血压等。

公开(公告)号：WO2008039496A3

公开(公告)日：2008-07-31

申请号：PCT/US2007020778

申请日：2007-09-26

Applicant: UNIV COLUMBIA ,  KIM PHILIP ,  HONG BYUNG HEE ,  LEE JU YOUNG ,  KIM KWANG S

Inventor： KIM PHILIP ,  HONG BYUNG HEE ,  LEE JU YOUNG ,  KIM KWANG S

IPC: D01F9/12 ,  B82B1/00 ,  F23C6/00

CPC classification number: B01J21/185 ,  B01J23/745 ,  B82Y30/00 ,  B82Y40/00 ,  C01B32/162 ,  C01B32/168 ,  C01B2202/06 ,  C01B2202/34 ,  D01F9/127 ,  Y10S977/742 ,  Y10S977/752 ,  Y10T428/2918

Abstract: Ultralong carbon nanotubes can be formed by placing a secondary chamber within a reactor chamber to restrict a flow to provide a laminar flow. Inner shells can be successively extracted from multi-walled carbon nanotubes (MWNTs) such as by applying a lateral force to an elongated tubular sidewall at a location between its two ends. The extracted shells can have varying electrical and mechanical properties that can be used to create useful materials, electrical devices, and mechanical devices.

Abstract translation: 超长碳纳米管可以通过在反应室内放置第二室来限制流动以提供层流而形成。 可以从多壁碳纳米管（MWNT）连续地提取内壳，例如通过在其两端之间的位置处向细长管状侧壁施加横向力。 提取的壳可以具有不同的电和机械性质，可用于创建有用的材料，电子设备和机械设备。

公开(公告)号：WO2012138147A2

公开(公告)日：2012-10-11

申请号：PCT/KR2012002575

申请日：2012-04-05

Applicant: LG LIFE SCIENCES LTD ,  YUN JUNG MIN ,  PARK KI SOOK ,  YOON JOO YONG ,  LEE JU YOUNG ,  KIM GEUN TAE ,  JUNG CHEOL KYU

Inventor： YUN JUNG MIN ,  PARK KI SOOK ,  YOON JOO YONG ,  LEE JU YOUNG ,  KIM GEUN TAE ,  JUNG CHEOL KYU

IPC: C07D403/04 ,  A61K31/4155 ,  A61P3/00 ,  A61P9/00

CPC classification number: C07D403/04

Abstract: The present invention relates to a crystalline form of the compound of formula (1), and a process for preparing the same.

Abstract translation: 本发明涉及式（1）化合物的结晶形式及其制备方法。

公开(公告)号：WO2011139107A2

公开(公告)日：2011-11-10

申请号：PCT/KR2011/003362

申请日：2011-05-04

Applicant: SK Chemicals Co.,Ltd. ,  RYU, Je Ho ,  KIM, Shin Ae ,  RYU, Keun Ho ,  KIM, Jae Sun ,  KIM, Nam Ho ,  HAN, Hye Young ,  KIM, Yong Hyuk ,  YOUN, Won-No ,  LEE, Yoon-Jung ,  SON, Hyun Joo ,  LEE, Bong-yong ,  PARK, Sung Hoon ,  LEE, Ju Young ,  LEE, Hyun Jung ,  JUNG, Hoe Chul ,  SHIN, Young Ah ,  LEE, Jung A ,  LEE, Bo Ram ,  SA, Joon Ho

Inventor： RYU, Je Ho ,  KIM, Shin Ae ,  RYU, Keun Ho ,  KIM, Jae Sun ,  KIM, Nam Ho ,  HAN, Hye Young ,  KIM, Yong Hyuk ,  YOUN, Won-No ,  LEE, Yoon-Jung ,  SON, Hyun Joo ,  LEE, Bong-yong ,  PARK, Sung Hoon ,  LEE, Ju Young ,  LEE, Hyun Jung ,  JUNG, Hoe Chul ,  SHIN, Young Ah ,  LEE, Jung A ,  LEE, Bo Ram ,  SA, Joon Ho

IPC: C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  A61K31/444 ,  A61K31/496 ,  A61P3/10 ,  A61P3/06

CPC classification number: C07D401/04 ,  C07D213/81 ,  C07D239/557 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract translation: 提供了吡啶酰胺和嘧啶-4-甲酰胺化合物，其制备方法，含有该组合物的药物组合物，以及使用该化合物作为预防，调节和治疗与糖皮质激素调节有关的疾病的药物的用途 化合物对11β-HSD1酶的选择性抑制活性。 本发明的吡啶酰胺和嘧啶-4-甲酰胺化合物是人源性11β-HSD1酶的选择性抑制剂，可用于预防，调节和治疗与糖皮质激素调节有关的疾病的药剂，其中人源性11β- 涉及HSD1酶，例如代谢综合征，例如1型和2型糖尿病，糖尿病后期并发症，潜伏性自身免疫性糖尿病成人（LAD A），胰岛素耐受综合征，肥胖症，葡萄糖耐量降低（IGT），空腹血糖受损 IFG），葡萄糖耐量受损，血脂异常，动脉粥样硬化，高血压等。

公开(公告)号：WO2005077942A1

公开(公告)日：2005-08-25

申请号：PCT/KR2005/000365

申请日：2005-02-07

Applicant: SK CHEMICALS, CO., LTD. ,  LEE, Nam Kyu ,  LEE, Ju Young ,  KIM, Jae-Sun ,  JUNG, Jae Yoon ,  UM, Key An ,  OH, Yong Ho ,  SHIN, Ho Chul ,  JANG, Woo Jae ,  IM, Guang-Jin ,  KIM, Tae Kon

Inventor： LEE, Nam Kyu ,  LEE, Ju Young ,  KIM, Jae-Sun ,  JUNG, Jae Yoon ,  UM, Key An ,  OH, Yong Ho ,  SHIN, Ho Chul ,  JANG, Woo Jae ,  IM, Guang-Jin ,  KIM, Tae Kon

IPC: C07D405/04

CPC classification number: C07D405/04

Abstract: The present invention relates to a novel method of synthesizing substituted benzopyran compounds, their novel intermediates and a method of their preparation thereof.

Abstract translation: 本发明涉及一种合成取代苯并吡喃化合物的新方法及其新型中间体及其制备方法。

公开(公告)号：WO2012138147A3

公开(公告)日：2012-10-11

申请号：PCT/KR2012/002575

申请日：2012-04-05

Applicant: LG LIFE SCIENCES LTD. ,  YUN, Jung Min ,  PARK, Ki Sook ,  YOON, Joo Yong ,  LEE, Ju Young ,  KIM, Geun Tae ,  JUNG, Cheol Kyu

Inventor： YUN, Jung Min ,  PARK, Ki Sook ,  YOON, Joo Yong ,  LEE, Ju Young ,  KIM, Geun Tae ,  JUNG, Cheol Kyu

IPC: C07D403/04 ,  A61K31/4155 ,  A61P3/00 ,  A61P9/00

Abstract: The present invention relates to a crystalline form of the compound of formula (1), and a process for preparing the same.

公开(公告)号：WO2013009140A3

公开(公告)日：2013-04-11

申请号：PCT/KR2012005617

申请日：2012-07-13

Applicant: SK CHEMICALS CO LTD ,  LEE JU YOUNG ,  RYU KEUN-HO ,  KIM JAE-SUN ,  KIM YONG-HYUK ,  SHIN DONG CHUL ,  LEE BONG-YONG ,  KANG SANG-HWAN ,  LEE HYUN JUNG ,  JUNG HOECHUL ,  SHIN YOUNG AH ,  PARK EUISUN ,  AHN JAESEUNG

Inventor： LEE JU YOUNG ,  RYU KEUN-HO ,  KIM JAE-SUN ,  KIM YONG-HYUK ,  SHIN DONG CHUL ,  LEE BONG-YONG ,  KANG SANG-HWAN ,  LEE HYUN JUNG ,  JUNG HOECHUL ,  SHIN YOUNG AH ,  PARK EUISUN ,  AHN JAESEUNG

IPC: C07D487/04

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-beta (TGF-beta) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

Abstract translation: 本发明提供了选择性抑制转化生长因子-β（TGF-β）I型受体（ALK5）和/或激活素I型受体的新型2-吡啶基取代的咪唑衍生物或其药学上可接受的盐或溶剂合物 （ALK4）; 包含其作为活性成分的药物组合物; 以及2-吡啶基取代的咪唑衍生物在制备用于预防或治疗由哺乳动物中ALK5和/或ALK4受体介导的疾病的药物中的用途。

公开(公告)号：WO2013009140A2

公开(公告)日：2013-01-17

申请号：PCT/KR2012/005617

申请日：2012-07-13

Applicant: SK CHEMICALS CO., LTD. ,  LEE, Ju Young ,  RYU, Keun-Ho ,  KIM, Jae-Sun ,  KIM, Yong-Hyuk ,  SHIN, Dong Chul ,  LEE, Bong-yong ,  KANG, Sang-hwan ,  LEE, Hyun Jung ,  JUNG, Hoechul ,  SHIN, Young Ah ,  PARK, Euisun ,  AHN, Jaeseung

Inventor： LEE, Ju Young ,  RYU, Keun-Ho ,  KIM, Jae-Sun ,  KIM, Yong-Hyuk ,  SHIN, Dong Chul ,  LEE, Bong-yong ,  KANG, Sang-hwan ,  LEE, Hyun Jung ,  JUNG, Hoechul ,  SHIN, Young Ah ,  PARK, Euisun ,  AHN, Jaeseung

IPC: C07D487/04

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

Abstract translation: 本发明提供了选择性抑制转化生长因子-β（TGF-β）I型受体（ALK5）和/或激活素I型受体的新型2-吡啶基取代的咪唑衍生物或其药学上可接受的盐或溶剂合物 （ALK4）; 包含其作为活性成分的药物组合物; 以及2-吡啶基取代的咪唑衍生物在制备用于预防或治疗由哺乳动物中ALK5和/或ALK4受体介导的疾病的药物中的用途。

公开(公告)号：WO2010150946A1

公开(公告)日：2010-12-29

申请号：PCT/KR2009/005906

申请日：2009-10-14

Applicant: SK HOLDINGS CO., LTD. ,  LIM, Sang ,Chul ,  UHM, Moo, Yong ,  CHO, Nahm, Ryune ,  LEE, Dae, Won ,  LEE, Ju, Young ,  KIM, Hui, Ho ,  LEE, Dong, Ho

Inventor： LIM, Sang ,Chul ,  UHM, Moo, Yong ,  CHO, Nahm, Ryune ,  LEE, Dae, Won ,  LEE, Ju, Young ,  KIM, Hui, Ho ,  LEE, Dong, Ho

IPC: C07D257/06

CPC classification number: C07D257/04 ,  C12P17/10

Abstract: Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester, comprising the asymmetric reduction of arylketone and the carbamation of alcohol.

Abstract translation: 公开了一种制备氨基甲酸（R）-1-芳基-2-四唑基乙基酯的方法，其包括芳基酮的不对称还原和醇的氨基甲酸酯化反应。

公开(公告)号：WO2009134030A1

公开(公告)日：2009-11-05

申请号：PCT/KR2009/001996

申请日：2009-04-17

Applicant: LG LIFE SCIENCES LTD. ,  HWANG, Kook Sang ,  CHUNG, Soon Min ,  KIM, Chang Ki ,  KIM, Bok Tae ,  LEE, Ju Young ,  KIM, Byeong Cheol ,  JOE, Goon Ho

Inventor： HWANG, Kook Sang ,  CHUNG, Soon Min ,  KIM, Chang Ki ,  KIM, Bok Tae ,  LEE, Ju Young ,  KIM, Byeong Cheol ,  JOE, Goon Ho

IPC: C07C231/02

CPC classification number: C07C231/02 ,  C07C235/68

Abstract: The present invention relates to a novel process for preparing iopromide which is used as a contrast agent for X-ray, wherein 5-methoxyacetylamino-2,4,6-triiodoisophthalic acid (2,3-diacetoxypropyl)amide chloride of formula (19) and 5-methoxyacetylamino-2,4,6-triiodoisophthalic acid [(2,3-dihydroxy-N-methylpropyl)-(2,3-diacetoxypropyl)]diamide of formula (20) are introduced as intermediates, by which a bismer by-product generated during the preparation process can be removed even without an additional removal procedure and thus iopromide with high purity can be prepared in high yield.

Abstract translation: 本发明涉及用作X射线造影剂的碘普罗胺的新方法，其中式（19）的5-甲氧基乙酰氨基-2,4,6-三碘代间苯二甲酸（2,3-二乙酰氧基丙基）酰胺氯 和作为中间体的式（20）的5-甲氧基乙酰氨基-2,4,6-三碘间苯二甲酸[（2,3-二羟基-N-甲基丙基） - （2,3-二乙酰氧基丙基）] - 二酰胺作为中间体， 在制备过程中产生的产物即使没有另外的去除程序也可以被除去，因此可以以高产率制备高纯度的碘普罗胺。